Test Price
2,800 AEDโ Home Collection Available
MYBPC3 Gene Dilated Cardiomyopathy Genetic Test in UAE | AED 2800 | DHA Licensed Laboratory
Executive Summary & Core Metrics
Comprehensive MYBPC3 gene sequencing using next-generation technology delivers 99.9% diagnostic sensitivity under DHA-licensed and ISO-certified laboratory processing.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed physicians.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MYBPC3 gene encodes cardiac myosin-binding protein C; mutations represent the most common genetic cause of familial dilated cardiomyopathy. This next-generation sequencing (NGS) test comprehensively analyses the entire MYBPC3 gene to identify pathogenic and likely pathogenic variants, guiding clinical surveillance, treatment decisions, and family risk assessment. The assay covers all coding exons, flanking intronic regions, and known deep intronic pathogenic variants with a minimum read depth of 100x, ensuring robust detection of single nucleotide variants and small insertions or deletions.
| Feature | Our Test โ NGS MYBPC3 Panel | Closest Alternative โ Sanger Sequencing |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) | Sanger Sequencing |
| Coverage | Full MYBPC3 gene + known deep intronic variants | Single hotspot mutation or limited exon set |
| Turnaround Time | 3โ4 Weeks | 4โ6 Weeks |
| Sensitivity | 99.9% | ~95% |
| Accreditation | ISO 9001:2015 & DHA Licensed | Variable |
| Price | 2800 AED | ~1500โ2000 AED (limited genes) |
| Sample Options | Blood, FTA Card, Extracted DNA | Blood only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
โThis genetic test powerfully refines risk stratification in families with dilated cardiomyopathy. Results must be interpreted within the full clinical context including echocardiographic findings, electrocardiogram data, and three-generation family history. A negative result does not exclude all inherited or acquired cardiomyopathies; a variant of uncertain significance should be re-evaluated periodically as population data evolve. Comprehensive pre-test and post-test genetic counselling is strongly recommended.โ
Important Safety Advisory
Medication Continuation: Never stop, alter, or adjust prescribed cardiac medications including beta-blockers, ACE inhibitors, or diuretics without direct instruction from your treating cardiologist. Abrupt discontinuation may lead to clinical deterioration.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: This test is not recommended for asymptomatic individuals without a family history of dilated cardiomyopathy or sudden cardiac death; variants of uncertain significance may cause undue anxiety. Not for standalone prenatal diagnosis unless guided by a genetics specialist.
Emergency Red Flags: If you experience chest pain, shortness of breath, fainting, palpitations, or signs of cardiac arrest, seek immediate emergency medical care. Genetic test results do not replace urgent cardiac evaluation.
Patient FAQ & Clinical Guidance
1. What is the MYBPC3 gene and why is it important in dilated cardiomyopathy?
The MYBPC3 gene provides instructions for cardiac myosin-binding protein C, a crucial component of the heart muscle sarcomere. Pathogenic variants in this gene weaken the structural integrity of cardiac muscle cells, leading to progressive left ventricular enlargement and reduced systolic functionโthe hallmark of dilated cardiomyopathy. Identifying a pathogenic MYBPC3 mutation confirms a hereditary aetiology, enables tailored clinical surveillance, and triggers cascade testing in at-risk relatives.
2. How is the test performed and what sample types are accepted?
A peripheral blood sample (2โ5 mL in EDTA tube), a dried blood spot on an FTA card, or previously extracted high-quality genomic DNA is accepted. Our VIP Mobile Phlebotomy team collects the sample at your home, office, or hotel between 8 AM and 11 PM daily, using temperature-controlled cold-chain transport to the ISO 9001:2015 certified laboratory. DNA undergoes targeted next-generation sequencing with at least 100x coverage across the entire MYBPC3 gene. Detected variants are classified according to ACMG/AMP guidelines. The turnaround time is 3โ4 weeks from sample receipt.
3. How do I interpret my result and what steps should I take afterward?
Positive (Pathogenic/Likely Pathogenic): Confirms a genetic cause for dilated cardiomyopathy. You should schedule a cardiology evaluation for echocardiogram, ECG, and discussion of preventive therapies including guideline-directed medical therapy. First-degree relatives should be offered cascade genetic testing.
Negative: Reduces the likelihood of a monogenic MYBPC3-related cardiomyopathy but does not exclude other genetic or acquired forms. Continue standard clinical surveillance based on family history and symptoms.
Variant of Uncertain Significance (VUS): This finding should not be used for clinical decision-making. Re-evaluation in 12โ24 months as population data expand is recommended. A complimentary tele-counselling session with our genetics team is provided to review your report and coordinate appropriate referrals.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This diagnostic service operates under DHA Facility License Number 1143 and adheres to all applicable UAE federal healthcare regulations. Data security and patient privacy are strictly governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data are encrypted, access-controlled, and processed exclusively within the UAE jurisdiction.
Clinical & Logistical Metadata
| Test Name | MYBPC3 Gene Dilated Cardiomyopathy Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), FTA Card, Extracted Genomic DNA |
| Methodology Used | Next-Generation Sequencing (NGS) โ Targeted Gene Panel |
| ICD-10-CM Code | I42.0 |
| LOINC Code | 93215-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians